Publication | Closed Access

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Systemic TreatmentClinical TrialsBimekizumab Versus UstekinumabPlaque PsoriasisBe VividClinical DermatologyPharmacotherapyDermatologyMedicine